Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Checked against the public recordLast updated Aug 25, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Drug: Iza-bren; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Non-squamous NSCLC, not amenable to treatment in curative intent. * Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation). * Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting. * Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed). Exclusion criteria: * Inadequate organ function and/or bone marrow reserve. * Leptomeningeal metastases or spinal cord compression. * Poorly controlled systemic medical conditions. * Other protocol-defined inclusion/exclusion criteria apply.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care buildingIrvine, California
- University of California, Irvine (UCI) Health - UC Irvine Medical CenterOrange, California
- Shaw Cancer CenterEdwards, Colorado
- Local Institution - 0085Gainesville, Florida
- Local Institution - 0142Pembroke Pines, Florida
- Piedmont HealthcareAtlanta, Georgia
- John B Amos Cancer CenterColumbus, Georgia
- Rush University Medical CenterChicago, Illinois
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Washington University School of MedicineSt Louis, Missouri
- Renown Regional Medical CenterReno, Nevada
- Perlmutter Cancer Center at NYU Langone Hospital - Long IslandMineola, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2026. Always confirm current availability with the study team.